Genetic susceptibility to atopic dermatitis

Allergology International

Volumn 57, Issue 1, 2008, Pages 39-56

  Kiyohara, Chikako ^a   Tanaka, Keiko ^b   Miyake, Yoshihiro ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atopic dermatitis; Epidemiology; Genetic polymorphism

Indexed keywords

ADENINE; ARGININE; CHEMOKINE; CHYMASE; CYTOKINE; CYTOKINE RECEPTOR; GLYCINE; GUANINE; INTERLEUKIN 13; INTERLEUKIN 4 RECEPTOR;

ALLERGIC RHINITIS; ANTIGEN PRESENTATION; ASTHMA; ATOPIC DERMATITIS; CHRONIC INFLAMMATION; CYTOTOXIC T LYMPHOCYTE; FOOD ALLERGY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HETEROZYGOTE; HUMAN; MULTIFACTORIAL INHERITANCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DISEASE;

EID: 40949147824     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.R-07-150     Document Type: Review

References (201)

1. Schultz Larsen F, Hanifin J. Epidemiology of atopic dermatitis. Immunol. Allergy Clin. North Am. 2002;22:1-24.
2. Sugiura H, Umemoto N, Deguchi H et al. Prevalence of childhood and adolescent atopic dermatitis in a Japanese population: comparison with the disease frequency examined 20 years ago. Acta Derm. Venereol. 1998;78:293-294.
3. Laughter D, Istvan JA, Tofte SJ, Hanifin JM. The prevalence of atopic dermatitis in Oregon schoolchildren. J. Am. Acad. Dermatol. 2000;43:649-655.
4. Schultz Larsen F, Diepgen T, Svensson A. The occurrence of atopic dermatitis in north Europe: an international questionnaire study. J. Am. Acad. Dermatol. 1996;34:760-764.
5. Bergmann RL, Edenharter G, Bergmann KE et al. Atopic dermatitis in early infancy predicts allergic airway disease at 5 years. Clin. Exp. Allergy 1998;28:965-970.
6. Taylor B, Wadsworth J, Wadsworth M, Peckham C. Changes in the reported prevalence of childhood eczema since the 1939-45 war. Lancet 1984;2:1255-1257.
7. Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J. Am. Acad. Dermatol. 1994;30:35-39.
8. Cookson W. The alliance of genes and environment in asthma and allergy. Nature 1999;402(Suppl):B5-B11.
9. Larsen FS, Holm NV, Henningsen K. Atopic dermatitis. A genetic-epidemiologic study in a population-based twin sample. J. Am. Acad. Dermatol. 1986;15:487-494.
10. Janeway CA Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today 1992;13:11-16.
11. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 2002;20:197-216.
12. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2001;2:675- 680.
13. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004;5:987-995.
14. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu. Rev. Immunol. 2003;21:335-376.
15. Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 2001;1:135-145.
16. McCurdy JD, Lin TJ, Marshall JS. Toll-like receptor 4-mediated activation of murine mast cells. Leukoc. Biol. 2001;70:977-984.
17. Supajatura V, Ushio H, Nakao A et al. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J. Clin. Invest. 2002;109:1351-1359.
18. Masuda A, Yoshikai Y, Aiba K, Matsuguchi T. Th2 cytokine production from mast cells is directly induced by lipopolysaccharide and distinctly regulated by c-Jun N-terminal kinase and p38 pathways. Immunol. 2002;169:3801- 3810.
19. Okumura S, Kashiwakura J, Tomita H et al. Identification of specific gene expression profiles in human mast cells mediated by Toll-like receptor 4 and FcepsilonRI. Blood 2003;102:2547-2554.
20. Malaviya R, Ikeda T, Ross E, Abraham SN. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 1996;381:77-80.
21. Echtenacher B, Mannel DN, Hultner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 1996;381:75- 77.
22. Supajatura V, Ushio H, Nakao A et al. Protective roles of mast cells against enterobacterial infection are mediated by Toll-like receptor 4. J. Immunol. 2001;167:2250-2256.
23. McLachlan JB, Hart JP, Pizzo SV et al. Mast cell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. Nat. Immunol. 2003;4:1199-1205.
24. Weidinger S, Klopp N, Rummler L et al. Association of NOD1 polymorphisms with atopic eczema and related phenotypes. J. Allergy Clin. Immunol. 2005;116:177-184.
25. Weidinger S, Klopp N, Rummler L et al. KORA study group. Association of CARD15 polymorphisms with atopy-related traits in a population-based cohort of Caucasian adults. Clin. Exp. Allergy 2005;35:866-872.
26. Kabesch M, Peters W, Carr D et al. Association between polymorphisms in caspase recruitment domain containing protein 15 and allergy in two German populations. J. Allergy Clin. Immunol. 2003;111:813- 817.
27. Lange J, Heinzmann A Zehle C, Kopp M. CT genotype of promotor polymorphism C159T in the CD14 gene is associated with lower prevalence of atopic dermatitis and lower IL-13 production. Pediatr. Allergy Immunol. 2005;16:456-457.
28. Sengler C, Haider A Sommerfeld C et al. Evaluation of the CD14 C-159 T polymorphism in the German Multicenter Allergy Study cohort. Clin. Exp. Allergy 2003;33:166-169.
29. Liang XH, Cheung W, Heng CK et al. CD14 promoter polymorphisms have no functional significance and are not associated with atopic phenotypes. Pharmacogenet. Genomics 2006;16:229-236.
30. Hashimoto S, Nakamura K Oyama N et al. Mannose-binding lectin (MBL) single nucleotide polymorphism is not associated with atopic dermatitis in Japanese patients. J. Dermatol. 2005;32:1038-1040.
31. Ahmad-Nejad P, Mrabet-Dahbi S, Breuer K et al. The toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype. J. Allergy Clin. Immunol. 2004;113:565-567.
32. Weidinger S, Novak N, Klopp N et al. Lack of association between Toll-like receptor 2 and Toll-like receptor 4 polymorphisms and atopic eczema. J Allergy Clin. Immunol. 2006;118:277-279.
33. Hoffjan S, Stemmler S, Parwez Q et al. Evaluation of the toll-like receptor 6 Ser249Pro polymorphism in patients with asthma, atopic dermatitis and chronic obstructive pulmonary disease. BMC Med. Genet. 2005;6:34.
34. Alam R. Chemokines in allergic inflammation. J. Allergy Clin. Immunol. 1997;99:273-277.
35. Gangur V, Oppenheim JJ. Are chemokines essential or secondary participants in allergic responses? Ann. Allergy Asthma Immunol. 2000;84:569-581.
36. IUIS/WHO Subcommittee on Chemokine Nomenclature, Chemokine/chemokine receptor nomenclature. Cytokine 2003;21:48-49.
37. Heath H, Qin S, Rao P et al. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J. Clin. Invest. 1997;99:178-184.
38. Uguccioni M, Mackay CR, Ochensberger B et al. High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. J. Clin. Invest. 1997;100:1137-1143.
39. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 1997;277:2005-2007.
40. Bonecchi R, Bianchi G, Bordignon PP et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 1998;187:129-134.
41. Bonecchi R, Sozzani S, Stine JT et al. Divergent effects of interleukin-4 and interferon-gamma on macrophage-derived chemokine production: an amplification circuit of polarized T helper 2 responses. Blood 1998;92:2668-2671.
42. Zingoni A, Soto H, Hedrick JA et al. The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J. Immunol. 1998;161:547-551.
43. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Canonica GW, Jasmin C, Azzarone B. Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J. Clin. Invest. 1998;101:2129-2139.
44. Ponath PD, Qin S, Ringler DJ et al. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J. Clin. Invest. 1996;97:604-612.
45. Cheng SS, Lukacs NW, Kunkel SL. Eotaxin/CCL11 is a negative regulator of neutrophil recruitment in a murine model of endotoxemia. Exp. Mol. Pathol. 2002;73:1-8.
46. Cheng SS, Lukacs NW, Kunkel SL. Eotaxin/CCL11 suppresses IL-8/CXCL8 secretion from human dermal microvascular endothelial cells. J. Immunol. 2002;168:2887-2894.
47. Kaburagi Y, Shimada Y, Nagaoka T et al. Enhanced production of CC-chemokines (RANTES, MCP-1, MIP-1alpha, MIP-1beta, and eotaxin) in patients with atopic dermatitis. Arch. Dermatol. Res. 2001;293:350-355.
48. Yawalkar N, Uguccioni M, Scharer J et al. Enhanced expression of eotaxin and CCR3 in atopic dermatitis. J Invest. Dermatol. 1999;113:43-48.
49. Park CW, Lee BH, Han HJ et al. Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis. Br. J. Dermatol. 2005;152:1173-1181.
50. Arakawa S, Hatano Y, Katagiri K et al. Effects of ultraviolet B irradiation on the production of regulated upon activation normal T-cell expressed and secreted protein in cultured human epidermal keratinocytes. Arch. Dermatol. Res. 2006;297:377-380.
51. Nickel R, Beck LA Stellate C, Schleimer RP. Chemokines and allergic disease. J. Allergy Clin. Immunol. 1999;104:723-742.
52. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol. Today 1998;19:568-574.
53. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-127.
54. Godiska R, Chantry D, Raport CJ et al. Monocyte chemotactic protein-4: tissue-specific expression and signaling through CC chemokine receptor-2. J. Leukoc. Biol. 1997;6:353-360.
55. Santamaria Babi LF, Perez Soler MT, Hauser C, Blaser K. Skin-homing T cells in human cutaneous allergic inflammation. Immunol. Res. 1995;14:317-324.
56. Campbell JJ, Haraldsen G, Pan J et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999;400:776-880.
57. Reiss Y, Proudfoot AE, Power CA et al. CC chemokine receptor (CCR) 4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J. Exp. Med. 2001;194:1541-1547.
58. He SH, Xie H, Zhang XJ, Wang XJ. Inhibition of histamine release from human mast cells by natural chymase inhibitors. Acta Pharmacol. Sin. 2004;25:822-826.
59. Tomimori Y, Tsuruoka N, Fukami H et al. Role of mast cell chymase in allergen-induced biphasic skin reaction. Biochem. Pharmacol. 2002;64:1187-1193.
60. Lazaar AL, Plotnick MI, Kucich U et al. Mast cell chymase modifies cell-matrix interactions and inhibits mitogen-induced proliferation of human airway smooth muscle cells. J. Immunol. 2002;169:1014-1020.
61. Molino M, Barnathan ES, Numerof R et al. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J. Biol. Chem. 1997;272:4043-4049.
62. Ishihara H, Connolly AJ, Zeng D et al. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997;386:502- 506.
63. Kozma GT, Falus A, Bojszko A et al. Lack of association between atopic eczema/dermatitis syndrome and polymorphisms in the promoter region of RANTES and regulatory region of MCP-1. Allergy 2002;57:160-163.
64. Nickel RG, Casolaro V, Wahn U et al. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J. Immunol. 2000;164:1612-1616.
65. Liu H, Chao D, Nakayama EE et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc. Natl. Acad. Sci. U.S.A. 1999;96:4581-4585.
66. Bai B, Tanaka K, Tazawa T et al. Association between RANTES promoter polymorphism -401A and enhanced RANTES production in atopic dermatitis patients. J. Dermatol. Sci. 2005;39:189-191.
67. Tsunemi Y, Saeki H, Nakamura K et al. Eotaxin gene single nucleotide polymorphisms in the promoter and exon regions are not associated with susceptibility to atopic dermatitis, but two of them in the promoter region are associated with serum IgE levels in patients with atopic dermatitis. J. Dermatol. Sci. 2002;29:222-228.
68. Suzuki K, Morokata T, Morihira K et al. In vitro and in vivo characterization of a novel CCR3 antagonist, YM-344031. Biochem. Biophys. Res. Commun. 2006;339:1217-1223.
69. Miyamasu M, Sekiya T, Ohta KR et al. Variations in the human CC chemokine eotaxin gene. Genes Immun. 2001;2:461-463.
70. Kakinuma T, Nakamura K, Wakugawa M et al. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity. J. Allergy Clin. Immunol. 2001;107:535-541.
71. Tsunemi Y, Komine M, Sekiya T et al. The -431C > T polymorphism of thymus and activation-regulated chemokine increases the promoter activity but is not associated with susceptibility to atopic dermatitis in Japanese patients. Exp. Dermatol. 2004;13:715-719.
72. Fukunaga K, Asano K, Mao XQ et al. Genetic polymorphisms of CC chemokine receptor 3 in Japanese and British asthmatics. Eur. Respir. J. 2001;17:59-63.
73. Zimmermann N, Bernstein JA, Rothenberg ME. Polymorphisms in the human CC chemokine receptor-3 gene. Biochim. Biophys. Acta 1998;1442:170- 176.
74. Kato H, Tsuchiya N, Izumi S et al. New variations of human CC-chemokine receptors CCR3 and CCR4. Genes Immun. 1999;1:97-104.
75. Tsunemi Y, Sekiya T, Saeki H et al. Lack of association of CCR3 single nucleotide polymorphism with atopic dermatitis in Japanese population. J. Dermatol. Sci. 2003;33:130-133.
76. Tsunemi Y, Sekiya T, Saeki H et al. Lack of association of CCR4 single nucleotide polymorphism with atopic dermatitis in Japanese patients. Acta Derm. Venereol. 2004;84:187-190.
77. Mao QX, Shirakawa T, Yoshikawa T et al. Association between genetic variants of mast-cell chymase and eczema. Lancet 1996;348:581-583. Erratum in: 1997;349:64.
78. Kawashima T, Noguchi E, Arinami T et al. No evidence for an association between a variant of the mast cell chymase gene and atopic dermatitis based on case-control and haplotype-relative-risk analyses. Hum. Hered. 1998;48:271-274.
79. Pascale E, Tarani L, Meglio P et al. Absence of association between a variant of the mast cell chymase gene and atopic dermatitis in an Italian population. Hum. Hered. 2001;51:177-179.
80. Tanaka K, Sugiura H, Uehara M et al. Association between mast cell chymase genotype and atopic eczema: comparison between patients with atopic eczema alone and those with atopic eczema and atopic respiratory disease. Clin. Exp. Allergy 1999;29:800-803.
81. Iwanaga T, McEuen A, Walls AF et al. Polymorphism of the mast cell chymase gene (CMA1) promoter region: lack of association with asthma but association with serum total immunoglobulin E levels in adult atopic dermathis. Clin. Exp. Allergy 2004;34:1037-1042.
82. Weidinger S, Rummler L, Klopp N et al. Association study of mast cell chymase polymorphisms with atopy. Allergy 2005;60:1256-1261.
83. Badertscher K, Bronnimann M, Karlen S et al. Mast cell chymase is increased in chronic atopic dermatitis but not in psoriasis. Arch. Dermatol. Res. 2005;296:503-536.
84. Groneberg DA, Bester C, Grutzkau A et al. Mast cells and vasculature in atopic dermatitis-potential stimulus of neoangiogenesis. Allergy 2005;60:90-97.
85. Imada T, Komorita N, Kobayashi F et al. Therapeutic potential of a specific chymase inhibitor in atopic dermatitis. Jpn. J. Pharmacol. 2002;90:214-217.
86. Watanabe N, Tomimori Y, Saito K et al. Chymase inhibitor improves dermatitis in NC/Nga mice. Int. Arch. Allergy Immunol. 2002;128:229-234.
87. Funauchi M, Ikoma S, Enomoto H, Horiuchi A. Decreased Th1-like and increased Th2-like cells in systemic lupus erythematosus. Scand. J. Rheumatol. 1998;27:219-224.
88. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 1989;7:145-173.
89. Romagnani S. The Th1/Th2 paradigm. Immunol. Today 1997;18:263-266.
90. Viallard JF, Pellegrin JL, Ranchin V et al. Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin. Exp. Immunol. 1999;115:189-195.
91. Cohn L, Homer RJ, Niu N, Bottomry K. T helper 1 cells and interferon gamma regulate allergic airway inflammation and mucus production. J. Exp. Med. 1999;190:1309-1318.
92. Cohn L, Tepper JS, Bottomly K. IL-4-independent induction of airway hyperresponsiveness by Th2, but not Th1, cells. J. Immunol. 1998;161:3813-3816.
93. Randolph DA, Stephens R, Carruthers CJ, Chaplin DD. Cooperation between Th1 and Th2 cells in a murine model of eosinophilic airway inflammation. J. Clin. Invest. 1999;104:1021-1029.
94. Hansen G, McIntire JJ, Yeung VP et al. CD4 (+) T helper cells engineered to produce latent TGF-beta1 reverse allergen-induced airway hyperreactivity and inflammation. J. Clin. Invest. 2000;105:61-70.
95. Bochner BS, Schleimer RP. The role of adhesion molecules in human eosinophil and basophil recruitment. J. Allergy Clin. Immunol. 1994;94:427-439.
96. Zhu Z, Homer RJ, Wang Z et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 1999;103:779-788.
97. Postlethwaite AE, Holness MA Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J. Clin. Invest. 1992;90:1479-1485.
98. Sempowski GD, Beckmann MP, Derdak S, Phipps RP. Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors. Role of IL-4 in enhancing fibroblast proliferation and collagen synthesis. J. Immunol. 1994;152:3606-3614.
99. Ohno I, Nitta Y, Yamauchi K et al. Transforming growth factor beta 1 (TGF beta 1) gene expression by eosinophils in asthmatic airway inflammation. Am. J. Respir. Cell Mol. Biol. 1996;15:404-409.
100. Reich K, Westphal G, Konig IR et al. Cytokine gene polymorphisms in atopic dermatitis. Br. J. Dermatol. 2003;148:1237-1241.
101. Shimizu M, Matsuda A Yanagisawa K et al. Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum. Mol. Genet. 2005;14:2919-2927.
102. Hoffjan S, Ostrovnaja I, Nicolae D et al. Genetic variation in immunoregulatory pathways and atopic phenotypes in infancy. J. Allergy Clin. Immunol. 2004;113:511-518.
103. Rafatpanah H, Bennett E, Pravica V et al. Association between novel GM-CSF gene polymorphisms and the frequency and severity of atopic dermatitis. J. Allergy Clin. Immunol. 2003;112:593-598.
104. . Kawashima T, Noguchi E, Arinami T et al. Linkage and association of an interleukin 4 gene polymorphism with atopic dermatitis in Japanese families. J. Med. Genet. 1998;35:502-504.
105. He JQ, Chan-Yeung M, Becker AB et al. Genetic variants of the IL13 and IL4 genes and atopic diseases in at-risk children. Genes Immun. 2003;4:385-389.
106. Chang YT, Lee WR, Yu CW et al. No association of cytokine gene polymorphisms in Chinese patients with atopic dermatitis. Clin. Exp. Dermatol. 2006;31:419-423.
107. Hosomi N, Fukai K, Oiso N et al. Polymorphisms in the promoter of the interleukin-4 receptor alpha chain gene are associated with atopic dermatitis in Japan. J. Invest. Dermatol. 2004;122:843-845.
108. Callard RE, Hamvas R, Chatterton C et al. Avon Longitudinal Study of Parents and Children. An interaction between the IL-4R alpha gene and infection is associated with atopic eczema in young children. Clin. Exp. Allergy 2002;32:990-993.
109. Oiso N, Fukai K, Ishii M. Interleukin 4 receptor alpha chain polymorphism Gln551Arg is associated with adult atopic dermatitis in Japan. Br. J. Dermatol. 2000;142:1003-1006.
110. Yamamoto N, Sugiura H, Tanaka K, Uehara M. Heterogeneity of interleukin 5 genetic background in atopic dermatitis patients: significant difference between those with blood eosinophilia and normal eosinophil levels. J. Dermatol. Sci. 2003;33:121-126.
111. Tsunemi Y, Saeki H, Nakamura K et al. Interleukin-12 p40 gene (IL12B) 3′-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J. Dermatol. Sci. 2002;30:161-166.
112. Takahashi N, Akahoshi M, Matsuda A et al. Association of the IL12RB1 promoter polymorphisms with increased risk of atopic dermatitis and other allergic phenotypes. Hum. Mol. Genet. 2005;14:3149-3159.
113. Hummelshoj T, Bodtger U, Datta P et al. Association between an interleukin-13 promoter polymorphism and atopy. Eur. J. Immunogenet. 2003;30:355-359.
114. Tsunemi Y, Saeki H, Nakamura K et al. Interleukin-13 gene polymorphism G4257A is associated with atopic dermatitis in Japanese patients. J. Dermatol. Sci. 2002;30:100-107.
115. Liu X, Nickel R, Beyer K et al. An IL13 coding region variant is associated with a high total serum IgE level and atopic dermatitis in the German multicenter atopy study (MAS-90). J. Allergy Clin. Immunol. 2000;106:167-170.
116. Novak N, Kruse S, Potreck J et al. Single nucleotide polymorphisms of the IL18 gene are associated with atopic eczema. J. Allergy Clin. Immunol. 2005;115:828-833. Erratum in: 2006;118:1319.
117. Arkwright PD, Chase JM, Babbage S et al. Atopic dermatitis is associated with a low-producer transforming growth factor beta (1) cytokine genotype. J. Allergy Clin. Immunol. 2001;108:281-284.
118. Aggarwal BB, Eessalu TE, Hass PE. Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature 1985;318:665-667.
119. Saeki H, Tsunemi Y, Asano N et al. Analysis of GM-CSF gene polymorphisms (3606T/C and 3928C/T) in Japanese patients with atopic dermatitis. Clin. Exp. Dermatol. 2006;31:278-280.
120. Tamura K Suzuki M, Arakawa H et al. Linkage and association studies of STAT6 gene polymorphisms and allergic diseases. Int. Arch.Allergy Immunol. 2003;131:33-38.
121. Kuwata S, Yanagisawa M, Saeki H et al. Polymorphisms of transporter associated with antigen processing genes in atopic dermatitis. J. Allergy Clin. Immunol. 1994;94:565-574.
122. Colonna M, Bresnahan M, Bahram S et al. Allelic variants of the human putative peptide transporter involved in antigen processing. Proc. Natl. Acad. Sci. U.S.A. 1992;89:3932-3936.
123. Powis SH, Rosenberg WMC, Hall M et al. TAP1 and TAP2 polymorphism in coeliac disease. Immunogenetics 1993;38:345-350.
124. Burney RO, Pile KD, Gibson K et al. Analysis of the MHC class II encoded components of the HLA class I antigen processing pathway in ankylosing spondylitis. Ann. Rheum. Dis. 1994;53:58-60.
125. Kuwata S, Yanagisawa M, Saeki H et al. Lack of primary association between transporter associated with antigen processing genes and atopic dermatitis. J. Allergy Clin. Immunol. 1995;96:1051-1060.
126. Rau H, Nicolay A Usadel KH et al. Polymorphisms of TAP1 and TAP2 genes in Graves' disease. Tissue Antigens 1997;49:16-22.
127. Takeuchi F, Nakano K, Matsuta K et al. Polymorphism of TAP1 and TAP2 in Japanese patients with rheumatoid arthritis. Tissue Antigens 1997;49:280-282.
128. Driscoll J, Brown MG, Finley D, Monaco JJ. MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature 1993;365:262-264.
129. Gaczynska M, Rock KL, Goldberg AL. Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 1993;365:264-267.
130. Lee HJ, Ha SJ, Han H, Kim JW. Distribution of HLA-A, B alleles and polymorphisms of TAP and LMP genes in Korean patients with atopic dermatitis. Clin. Exp. Allergy 2001;31:1867-1874.
131. Kuwata S, Yanagisawa M, Nakagawa H et al. HLA-DM gene polymorphisms in atopic dermatitis. J. Allergy Clin. Immunol. 1996;98:S192-S200.
132. Bijlmakers MJ, Ploegh HL. Putting together an MHC class I molecule. Curr. Opin. Immunol. 1993;5:21-26.
133. Trowsdale Hanson I, Mockridge I et al. Sequence encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters. Nature 1990;348:741-744.
134. Powis SH, Tonks S, Mockridge I et al. Alleles and haplotypes of the MHC-encoded ABC transporters TAP1 and TAP2. Immunogenetics 1993;37:373-380.
135. Powis SJ, Deverson EV, Coadwell WJ et al. Effect of polymorphism of a MHC-linked transporter on the peptides assembled in a class I molecule. Nature 1992;357:211-215.
136. Ismail A, Bousaffara R, Kaziz J et al. Polymorphism in transporter antigen peptides gene (TAP1) associated with atopy in Tunisians. J. Allergy Clin. Immunol. 1997;99:216-223.
137. Linsley PS, Brady W, Grosmaire L et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 1991;173:721-730.
138. Linsley PS, Brady W, Urnes MG et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 1991;174:561- 569.
139. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997;7:445-450.
140. Schmidt-Weber CB, Blaser K. T-cell tolerance in allergic response. Allergy 2002;57:762-768.
141. Novak N, Allam J-P, Betten H et al. The role of antigen presenting cells at distinct anatomic sites: they accelerate and they slow down allergies. Allergy 2004;59:5-14.
142. Egelrud T, Lundstrom A. A chymotrypsin-like proteinase that may be involved in desquamation in plantar stratum corneum. Arch. Dermatol. Res. 1991;283:108-112.
143. Egelrud T. Purification and preliminary characterisation of stratum corneum chymotryptic enzyme: A proteinase that may be Involved in Desquamation. J. Invest. Dermatol. 1993;101:200-204.
144. Sondell B, Thornell LE, Stigbrand T, Egelrud T. Immunolocalisation of stratum corneum chymotryptic enzyme in human skin and oral epithelium with monoclonal antibodies: Evidence of a Proteinase Specifically Expressed in Keratinizing Squamous Epithelia. J. Histochem. Cytochem. 1994;42:459-465.
145. Ekholm E, Egelrud T. The expression of stratum corneum chymotryptic enzyme in human anagen hair follicles: Further evidence for its Involvement in Desquamation-like process. Br. J. Dermatol. 1998;139:585-590.
146. Lundstrom A Egelrud T Stratum corneum chymotryptic enzyme: A Proteinase which may be Generally Present in the Stratum Corneum and with a Possible Involvement in Desquamation. Acta Derm. Venereol. 1991;71:471-474.
147. Franzke CW, Baici A, Bartels J et al. Antileukoprotease inhibits stratum corneum chymotryptic enzyme - evidence for a regulative function in desquamation. J. Biol. Chem. 1996;271:21886-21890.
148. Hansson L, Backman A, Ny A et al. Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: A Model for Chronic Itchy Dermatitis. J. Invest. Dermatol. 2002;118:444-449.
149. Prokunina L, Castillejo-Lopez C, Oberg F et al. regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat. Genet. 2002;32:666-669.
150. Taniuchi I, Osato M, Egawa T et al. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell 2002;111:621-633.
151. Helms C, Cao L, Krueger JG et al. putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat. Genet. 2003;35:349-356.
152. Komatsu N, Takata M, Otsuki N et al. Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides. J. Invest. Dermatol. 2002;118: 436-443.
153. Mitsudo K Jayakumar A, Henderson Y et al. Inhibition of serine proteinases plasmin, trypsin, subtilisin A cathepsin G, and elastase by LEKTI: a kinetic analysis. Biochemistry 2003;42:3874-3881.
154. Ekholm IE, Brattsand M, Egelrud T. Stratum corneum tryptic enzyme in normal epidermis: a missing link in the desquamation process? J. Invest. Dermatol. 2000;114:56-63.
155. Ueda H, Howson JM, Esposito L et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003;423:506-511.
156. Maurer M, Loserth S, Kolb-Maurer A et al. polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 2002;54:1-8.
157. Ligers A, Teleshova N, Masterman T et al. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun. 2001;2:145-152.
158. Kouki T, Sawai Y, Gardine CA et al. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J. Immunol. 2000;165:6606- 6011.
159. Yang KD, Liu CA Chang JC et al. Polymorphism of the immune-braking gene CTLA-4 (+49) involved in gender discrepancy of serum total IgE levels and allergic diseases. Clin. Exp. Allergy 2004;34:32-37.
160. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. 2001;22:184-204.
161. Brattsand M, Egelrud T. Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. J. Biol. Chem. 1999;274:30033-30040.
162. Hansson L, Stromqvist M, Backman A et al. Cloning, expression, and characterization of stratum corneum chymotryptic enzyme. A skin-specific human serine proteinase. J. Biol.Chem. 1994;269:19420-19426.
163. Simon M, Jonca N, Guerrin M et al. Refined characterization of corneodesmosin proteolysis during terminal differentiation of human epidermis and its relationship to desquamation. J. Biol. Chem. 2001;276: 20292-20299. Erratum in: 2001;276:47742-47743.
164. Caubet C, Jonca N, Brattsand M et al. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J. Invest. Dermatol. 2004;122:1235-1244.
165. Clements JA, Willemsen NM, Myers SA Dong Y. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit. Rev. Clin. Lab. Sci. 2004;41:265-312.
166. Diamandis EP, Scorilas A, Kishi T et al. Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. Clin. Biochem. 2004;37:230-237.
167. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 2004;4:876-890.
168. Diamandis EP, Borgono CA, Scorilas A et al. Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis. Tumour Biol. 2003;24:299-309.
169. Dong Y, Kaushal A, Brattsand M et al. Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin. Cancer Res. 2003;9:1710- 1720.
170. Vasilopoulos Y, Cork MJ, Murphy R et al. Genetic association between an AACC insertion in the 3′UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis. J. Invest. Dermatol. 2004;123:62-66.
171. Hosomi N, Fukai K, Oiso N et al. No association between atopic dermatitis and the SLC9A3R1-NAT9 RUNX1 binding site polymorphism in Japanese patients. Clin. Exp. Dermatol. 2005;30:192-193.
172. Chavanas S, Bodemer C, Rochat A et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat. Genet. 2000;25:141-142.
173. Walley AJ, Chavanas S, Moffatt MF et al. Gene polymorphism in Netherton and common atopic disease. Nat. Genet. 2001;29:175-178.
174. Fölster-Holst R, Stoll M, Koch WA et al. Lack of association of SPINK5 polymorphisms with nonsyndromic atopic dermatitis in the population of Northern Germany. Br. J. Dermatol. 2005;152:1365-1367.
175. Kato A, Fukai K, Oiso N et al. Association of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population. Br. J. Dermatol. 2003;148:665-669.
176. Nishio Y, Noguchi E, Shibasaki M et al. Association between polymorphisms in the SPINK5 gene and atopic dermatitis in the Japanese. Genes Immun. 2003;4:515-517.
177. Kabesch M, Carr D, Weiland SK von Mutius E. Association between polymorphisms in serine protease inhibitor, kazal type 5 and asthma phenotypes in a large German population sample. Clin. Exp. Allergy 2004;34:340-345.
178. Levy M, Caraco Y, Geisslinger G. Drug acetylation in liver disease. Clin. Pharmacokinet. 1998;34:219-226.
179. Nebert DW. Polymorphism in drug-metabolizing enzymes, what is their clinical relevance and why do they exist? Am. J. Hum. Genet. 1997;60:265-271.
180. Barnes PJ. Reactive oxygen species and airway inflammation. Free Rad. Biol. Med. 1990;9:235-243.
181. Hayes JD, Strange RC. Potential contribution of the glutathione S-transferase supergene family to resistance to oxidative stress. Free Rad. Res. Commun. 1995;22:193-207.
182. Strange RC, Fryer AA. The glutathione S-transferases: influence of polymorphism on susceptibility to non familial cancers. In: Boffetta P, Caporaso N, Cuzick J, Lang M, Vineis P (eds). Metabolic polymorphisms and cancer. Lyon, France: IARC Scientific Publications, 1999;231-249.
183. Weber WW, Hein DW. N-Acetylation pharmacogenetics. Pharmacol. Rev. 1985;37:25-79.
184. Hein DW, Doll MA, Fretland AJ et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomark. Prev. 2000;9:29-42.
185. Badawi AF, Hirvonen A, Bell DA et al. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res. 1995;55:5230-5237.
186. Kadlubar FF, Badawi AF. Genetic susceptibility and carcinogen-DNA adduct formation in human urinary bladder carcinogenesis. Toxicol. Lett. 1995;82/83:627-632.
187. O'Neil WM, Gilfix BM, DiGirolamo A et al. N-acetylation among HIV positive patients with AIDS. When is fast, fast and slow, slow? Clin. Pharmacol. Ther. 1997;62:261-271.
188. Zielinska E, Niewirowski W, Bodalski J et al. Arylamine N-acetyltransferase (NAT2) gene mutations in children with allergic diseases. Clin. Pharmacol. Ther. 1997;62:635-642.
189. Vavilin VA, Safronova OG, Lyapunova AA et al. Interaction of GSTM1, GSTT1, and GSTP1 genotypes in determination of predisposition to atopic dermatitis. Bull. Exp. Biol. Med. 2003;136:388-391.
190. Blum M, Demierre A, Grant DM et al. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc. Natl. Acad. Sci. U.S.A. 1991;88:5237-5241.
191. Vatsis KP, Martell KS, Weber WW. Diverse point mutations in human gene for polymorphic N-acetyltransferase. Proc. Natl. Acad. Sci. U.S.A. 1991;88:6333-6337.
192. Golka K, Prior V, Blaszkewicz M, Bolt HM. The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences. Toxicol. Lett. 2002;128:229-241.
193. Weber WW. Acetylation. Birth Defects Orig. Artic. Ser. 1990;26:43-65.
194. Grundmann M, Earl CD, Sautter J et al. Slow N-acetyl-transferase 2 status leads to enhanced intrastriatal dopamine depletion in 6-hydroxydopamine-lesioned rats. Exp. Neurol. 2004;187:199-202.
195. Makarova SI, Dodunova EM, Ivanova GG et al. Polymorphism of arylamine-N-acetyltransferase 2 gene is associated with the risk of atopic dermatitis. Bull. Exp. Biol. Med. 2005;139:662-664.
196. Brocvielle H, Muret P, Goydadin AC et al. N-acetyl-transferase 2 acetylation polymorphism: prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects. Skin Pharmacol. Appl. Skin Physiol. 2003;16:386-392.
197. Wacholder S, Chanock S, Garcia-Closas M et al. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J. Natl. Cancer Inst. 2004;96:434-442.
198. Khoury M, Beaty TH, Cohen BH. Fundamentals of Genetic Epidemiology. Monographs in Epidemiology and Biostatistics. New York: Oxford University Press, 1993.
199. Hoh J, Wille A, Ott J. Trimming, weighting, and grouping SNPs in human case-control association studies. Genome Res. 2001;11:2115-2119.
200. Kiyohara C. Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of colorectal cancer. J. Epidemiol. 2000;10:349-360.
201. Kiyohara C, Yoshimasu K, Shirakawa T, Hopkin JM. Genetic polymorphisms and environmental risk of lung cancer: a review. Rev. Environ. Health. 2004;19:15-38.